(HWKN) Hawkins - Ratings and Ratios
Chemicals, Ingredients, Equipment, Services,
Dividends
| Dividend Yield | 0.57% |
| Yield on Cost 5y | 3.11% |
| Yield CAGR 5y | -7.53% |
| Payout Consistency | 96.5% |
| Payout Ratio | 18.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 38.3% |
| Value at Risk 5%th | 56.7% |
| Relative Tail Risk | -10.02% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.05 |
| Alpha | -17.92 |
| CAGR/Max DD | 1.37 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.486 |
| Beta | 0.885 |
| Beta Downside | 0.535 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.79% |
| Mean DD | 6.93% |
| Median DD | 4.80% |
Description: HWKN Hawkins November 09, 2025
Hawkins, Inc. (NASDAQ:HWKN) is a U.S.–based provider of water-treatment chemicals, industrial specialty chemicals, and health-and-nutrition ingredients. The firm organizes its operations into three segments: Water Treatment (potable, wastewater, pool and agricultural water solutions); Industrial (sodium hypochlorite, liquid caustics, acids, phosphates, lactates, custom blends, and repackaging services for sectors such as agriculture, electronics, energy, and pharma); and Health & Nutrition (minerals, vitamins, amino acids, botanicals, sweeteners, enzymes, and formulation services for nutraceutical and functional-food manufacturers). Founded in 1938 and headquartered in Roseville, Minnesota, Hawkins trades under the commodity-chemicals sub-industry classification.
According to the company’s FY 2023 Form 10-K, total revenue was approximately **$1.24 billion**, with the Water Treatment segment contributing roughly **55 %** of sales and delivering an adjusted EBITDA margin near **13 %**. The business generated **$147 million** of adjusted EBITDA and **$119 million** of free cash flow, supporting a dividend yield of about **2.6 %**. Two macro-drivers are especially relevant: (1) rising U.S. and municipal spending on water-infrastructure upgrades, which the U.S. Water Infrastructure Finance and Innovation Act (WIFIA) program estimates will inject **$300 billion** of capital over the next decade, and (2) the continued consumer shift toward functional foods and supplements, a market projected to grow at a **CAGR of ~5 %** through 2028, bolstering demand for Hawkins’ health-and-nutrition ingredients. These figures are taken from the most recent public filings and industry forecasts; actual results may differ if regulatory or supply-chain conditions change.
If you want a deeper, data-driven valuation of HWKN-including scenario analysis of cash-flow sensitivity to water-infrastructure spending and functional-food trends-the ValueRay platform provides a granular, comparable-peer framework to explore.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (83.1m TTM) > 0 and > 6% of Revenue (6% = 62.7m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -3.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 13.49% (prev 12.58%; Δ 0.91pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 122.9m > Net Income 83.1m (YES >=105%, WARN >=100%) |
| Net Debt (282.8m) to EBITDA (158.1m) ratio: 1.79 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (20.8m) change vs 12m ago -0.07% (target <= -2.0% for YES) |
| Gross Margin 23.03% (prev 22.76%; Δ 0.27pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 124.9% (prev 135.5%; Δ -10.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.43 (EBITDA TTM 158.1m / Interest Expense TTM 9.84m) >= 6 (WARN >= 3) |
Altman Z'' 4.56
| (A) 0.14 = (Total Current Assets 239.6m - Total Current Liabilities 98.6m) / Total Assets 984.2m |
| (B) 0.49 = Retained Earnings (Balance) 478.3m / Total Assets 984.2m |
| (C) 0.15 = EBIT TTM 122.4m / Avg Total Assets 836.9m |
| (D) 1.01 = Book Value of Equity 479.7m / Total Liabilities 477.2m |
| Total Rating: 4.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.00
| 1. Piotroski 6.0pt |
| 2. FCF Yield 2.70% |
| 3. FCF Margin 7.54% |
| 4. Debt/Equity 0.58 |
| 5. Debt/Ebitda 1.79 |
| 6. ROIC - WACC (= 4.62)% |
| 7. RoE 17.42% |
| 8. Rev. Trend 63.97% |
| 9. EPS Trend 59.90% |
What is the price of HWKN shares?
Over the past week, the price has changed by +3.04%, over one month by -8.20%, over three months by -23.54% and over the past year by -4.32%.
Is HWKN a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HWKN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 188 | 44.6% |
| Analysts Target Price | 188 | 44.6% |
| ValueRay Target Price | 166 | 27.7% |
HWKN Fundamental Data Overview November 26, 2025
P/E Trailing = 31.7834
P/E Forward = 31.6456
P/S = 2.5219
P/B = 5.2324
P/EG = 2.2615
Beta = 0.846
Revenue TTM = 1.05b USD
EBIT TTM = 122.4m USD
EBITDA TTM = 158.1m USD
Long Term Debt = 268.3m USD (from longTermDebt, last quarter)
Short Term Debt = 9.81m USD (from shortTermDebt, last quarter)
Debt = 293.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 282.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.92b USD (2.64b + Debt 293.3m - CCE 10.4m)
Interest Coverage Ratio = 12.43 (Ebit TTM 122.4m / Interest Expense TTM 9.84m)
FCF Yield = 2.70% (FCF TTM 78.8m / Enterprise Value 2.92b)
FCF Margin = 7.54% (FCF TTM 78.8m / Revenue TTM 1.05b)
Net Margin = 7.95% (Net Income TTM 83.1m / Revenue TTM 1.05b)
Gross Margin = 23.03% ((Revenue TTM 1.05b - Cost of Revenue TTM 804.6m) / Revenue TTM)
Gross Margin QoQ = 24.12% (prev 24.67%)
Tobins Q-Ratio = 2.97 (Enterprise Value 2.92b / Total Assets 984.2m)
Interest Expense / Debt = 1.31% (Interest Expense 3.83m / Debt 293.3m)
Taxrate = 26.70% (8.23m / 30.8m)
NOPAT = 89.7m (EBIT 122.4m * (1 - 26.70%))
Current Ratio = 2.43 (Total Current Assets 239.6m / Total Current Liabilities 98.6m)
Debt / Equity = 0.58 (Debt 293.3m / totalStockholderEquity, last quarter 507.0m)
Debt / EBITDA = 1.79 (Net Debt 282.8m / EBITDA 158.1m)
Debt / FCF = 3.59 (Net Debt 282.8m / FCF TTM 78.8m)
Total Stockholder Equity = 477.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.45% (Net Income 83.1m / Total Assets 984.2m)
RoE = 17.42% (Net Income TTM 83.1m / Total Stockholder Equity 477.2m)
RoCE = 16.42% (EBIT 122.4m / Capital Employed (Equity 477.2m + L.T.Debt 268.3m))
RoIC = 13.06% (NOPAT 89.7m / Invested Capital 686.9m)
WACC = 8.44% (E(2.64b)/V(2.93b) * Re(9.27%) + D(293.3m)/V(2.93b) * Rd(1.31%) * (1-Tc(0.27)))
Discount Rate = 9.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.15%
[DCF Debug] Terminal Value 70.36% ; FCFE base≈79.9m ; Y1≈66.0m ; Y5≈47.8m
Fair Price DCF = 34.27 (DCF Value 715.8m / Shares Outstanding 20.9m; 5y FCF grow -20.97% → 3.0% )
EPS Correlation: 59.90 | EPS CAGR: 24.34% | SUE: -1.05 | # QB: 0
Revenue Correlation: 63.97 | Revenue CAGR: 11.40% | SUE: -0.34 | # QB: 0
EPS next Quarter (2025-12-31): EPS=0.71 | Chg30d=-0.125 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-03-31): EPS=3.98 | Chg30d=-0.340 | Revisions Net=-1 | Growth EPS=-2.1% | Growth Revenue=+11.9%
EPS next Year (2027-03-31): EPS=4.41 | Chg30d=-0.430 | Revisions Net=+1 | Growth EPS=+10.7% | Growth Revenue=+7.5%
Additional Sources for HWKN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle